Top Companies' AI Moves

Today's Stories

1. 1

   Opsin partners with Anthropic to help companies manage AI safety rules

   Opsin, which helps companies follow AI safety regulations, integrated with Claude's Compliance API on June 12th. This partnership lets businesses monitor and control their AI usage when using Anthropic's Claude chatbot services. The integration addresses growing concerns about AI governance as more companies deploy AI tools.

   Companies using Claude for business tasks now have better tools to ensure they're following AI safety regulations and internal policies.

2. 2

   Vertiv buys cooling company ThermoKey to tackle AI data center heat problem

   Infrastructure company Vertiv completed its acquisition of ThermoKey on June 12th to expand its cooling solutions for AI data centers. AI computing generates enormous amounts of heat, requiring specialized cooling systems to prevent equipment failure. The purchase strengthens Vertiv's ability to serve the rapidly growing AI infrastructure market.

   Better cooling technology could help reduce the massive energy costs of running AI services, potentially making AI tools cheaper for consumers.

3. 3

   ServiceNow and IBM team up to bring AI to outdated corporate software

   ServiceNow, which makes workflow management software for businesses, partnered with IBM to integrate AI into legacy enterprise systems. The collaboration aims to modernize old corporate software that companies rely on but struggle to update. ServiceNow's Now Assist AI tool is seeing strong demand as businesses seek to automate routine tasks.

   Office workers may soon see AI assistants helping with common workplace tasks like IT support requests and HR processes, even in companies using older software systems.

4. 4

   Bristol Myers Squibb overhauls operations with AI for drug development

   Pharmaceutical giant Bristol Myers Squibb is implementing AI across its operations to accelerate drug discovery and development. The company is using AI to analyze clinical trial data and identify promising cancer treatments more quickly. This represents a major shift in how traditional pharmaceutical companies approach research and development.

   AI-powered drug development could lead to faster approval of new medicines and potentially lower costs for patients needing specialized treatments.